Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 565

1.
2.

Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.

Burns JM Jr, Miura K, Sullivan J, Long CA, Barnwell JW.

Malar J. 2016 Mar 15;15:159. doi: 10.1186/s12936-016-1226-5.

3.

The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites.

Darko CA, Angov E, Collins WE, Bergmann-Leitner ES, Girouard AS, Hitt SL, McBride JS, Diggs CL, Holder AA, Long CA, Barnwell JW, Lyon JA.

Infect Immun. 2005 Jan;73(1):287-97.

4.

Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01.

Otsyula N, Angov E, Bergmann-Leitner E, Koech M, Khan F, Bennett J, Otieno L, Cummings J, Andagalu B, Tosh D, Waitumbi J, Richie N, Shi M, Miller L, Otieno W, Otieno GA, Ware L, House B, Godeaux O, Dubois MC, Ogutu B, Ballou WR, Soisson L, Diggs C, Cohen J, Polhemus M, Heppner DG Jr, Ockenhouse CF, Spring MD.

Malar J. 2013 Jan 23;12:29. doi: 10.1186/1475-2875-12-29.

5.

Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses.

Lyon JA, Angov E, Fay MP, Sullivan JS, Girourd AS, Robinson SJ, Bergmann-Leitner ES, Duncan EH, Darko CA, Collins WE, Long CA, Barnwell JW.

PLoS One. 2008 Jul 30;3(7):e2830. doi: 10.1371/journal.pone.0002830.

6.

Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys.

Kumar S, Yadava A, Keister DB, Tian JH, Ohl M, Perdue-Greenfield KA, Miller LH, Kaslow DC.

Mol Med. 1995 Mar;1(3):325-32.

7.
8.

High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model.

Dutta S, Sullivan JS, Grady KK, Haynes JD, Komisar J, Batchelor AH, Soisson L, Diggs CL, Heppner DG, Lanar DE, Collins WE, Barnwell JW.

PLoS One. 2009 Dec 3;4(12):e8138. doi: 10.1371/journal.pone.0008138.

9.

Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay.

Miura K, Zhou H, Diouf A, Moretz SE, Fay MP, Miller LH, Martin LB, Pierce MA, Ellis RD, Mullen GE, Long CA.

Clin Vaccine Immunol. 2009 Jul;16(7):963-8. doi: 10.1128/CVI.00042-09. Epub 2009 May 13.

10.

Antibody responses to a novel Plasmodium falciparum merozoite surface protein vaccine correlate with protection against experimental malaria infection in Aotus monkeys.

Cavanagh DR, Kocken CH, White JH, Cowan GJ, Samuel K, Dubbeld MA, Voorberg-van der Wel A, Thomas AW, McBride JS, Arnot DE.

PLoS One. 2014 Jan 8;9(1):e83704. doi: 10.1371/journal.pone.0083704. eCollection 2014.

11.

Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria.

Stowers AW, Kennedy MC, Keegan BP, Saul A, Long CA, Miller LH.

Infect Immun. 2002 Dec;70(12):6961-7.

12.

Antibody levels to multiple malaria vaccine candidate antigens in relation to clinical malaria episodes in children in the Kasena-Nankana district of Northern Ghana.

Dodoo D, Atuguba F, Bosomprah S, Ansah NA, Ansah P, Lamptey H, Egyir B, Oduro AR, Gyan B, Hodgson A, Koram KA.

Malar J. 2011 May 1;10:108. doi: 10.1186/1475-2875-10-108.

13.
14.

Impact of pre-existing MSP1(42)-allele specific immunity on potency of an erythrocytic Plasmodium falciparum vaccine.

Bergmann-Leitner ES, Duncan EH, Mease RM, Angov E.

Malar J. 2012 Sep 7;11:315. doi: 10.1186/1475-2875-11-315.

15.

Anemia and antibodies to the 19-kDa fragment of MSP1 during Plasmodium falciparum infection in Aotus monkeys.

Gozalo AS, Lucas CM, Qin J, Hall BT, Magill AJ.

Comp Med. 2007 Aug;57(4):396-401.

PMID:
17803055
16.

Identification of Plasmodium falciparum reticulocyte binding protein homologue 5-interacting protein, PfRipr, as a highly conserved blood-stage malaria vaccine candidate.

Ntege EH, Arisue N, Ito D, Hasegawa T, Palacpac NMQ, Egwang TG, Horii T, Takashima E, Tsuboi T.

Vaccine. 2016 Nov 4;34(46):5612-5622. doi: 10.1016/j.vaccine.2016.09.028. Epub 2016 Sep 28.

PMID:
27692771
17.

Passive transfer of growth-inhibitory antibodies raised against yeast-expressed recombinant Plasmodium falciparum merozoite surface protein-1(19).

Gozalo A, Lucas C, Cachay M, Wellde BT, Hall T, Bell B, Wood J, Watts D, Wooster M, Lyon JA, Moch JK, Haynes JD, Williams JS, Holland C, Watson E, Kester KE, Kaslow DC, Ballou WR.

Am J Trop Med Hyg. 1998 Dec;59(6):991-7.

PMID:
9886211
18.

Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness.

Stanisic DI, Richards JS, McCallum FJ, Michon P, King CL, Schoepflin S, Gilson PR, Murphy VJ, Anders RF, Mueller I, Beeson JG.

Infect Immun. 2009 Mar;77(3):1165-74. doi: 10.1128/IAI.01129-08. Epub 2009 Jan 12.

19.

A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria.

Chang SP, Case SE, Gosnell WL, Hashimoto A, Kramer KJ, Tam LQ, Hashiro CQ, Nikaido CM, Gibson HL, Lee-Ng CT, Barr PJ, Yokota BT, Hut GS.

Infect Immun. 1996 Jan;64(1):253-61.

20.

Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial.

Stowers AW, Cioce V, Shimp RL, Lawson M, Hui G, Muratova O, Kaslow DC, Robinson R, Long CA, Miller LH.

Infect Immun. 2001 Mar;69(3):1536-46.

Supplemental Content

Support Center